The clinical impact of DNA methylation frequencies of JAK2 negative regulators in patients with essential Thrombocythemia

详细信息	查看全文 | 推荐本文 |

• 作者：Mathilde Fö ; dermayr^a ; ^{mathilde.foedermayr@elisabethinen.or.at} ; Otto Zach^a ; Maria Huber^a ; Sigrid Machherndl-Spandl^a ; Soraya Wö ; lfl^b ; Hans-Christian Bö ; smü ; ller^c ; Sonja Hasenschwandtner^d ; Sonja Burgstaller^e ; Otto Krieger^a ; Dieter Lutz^a ; Ansgar Weltermann^a ; Hanns Hauser^a
• 关键词：SOCS1 ; SOCS3 ; PTPN6 ; DNA methylation ; Essential Thrombocythemia
• 刊名：Leukemia Research
• 出版年：2012
• 期刊代码：186_01452126
• 类别：med
• 出版时间：May, 2012
• 卷：36
• 期：5
• 页码：588-590
• 文件大小：152 K

摘要

Suppressors of cytokine signalling (SOCS) and protein tyrosine phosphatase (PTPN) proteins are negative regulators of Janus Kinase 2 (JAK2). They are thought to be involved in the molecular pathogenesis of essential thrombocythaemia (ET) particularly in patients with unmutated JAK2. In this study we compared DNA methylation of SOCS1, SOCS3 and PTPN6 in peripheral blood cells between 39 ET patients (24 JAK2 V617F mutated) and 22 healthy controls by methylation specific PCR (MSP) and analysed the clinical outcome of patients with respect to DNA methylation. In SOCS1, ET patients showed significantly less methylation (P < 0.05) than healthy controls, and in SOCS3 and PTPN6 such a tendency was shown. However, there were no significant differences in the methylation frequencies between JAK2 wildtype and mutated ET patients. In addition, no correlation was detected between methylation of SOCS and PTPN and any clinical outcome parameters. Taken together, regarding the genomic regions investigated our data indicate a minor role of methylation of JAK2 negative regulators for the clinical course of ET.